Tanezumab: A In-depth Dive into the 880266-57-9 Immunoglobulin Product
Tanezumab, identified by the research designation 880266-57-9, represents a targeted antibody solution demonstrating significant potential in alleviating chronic osteoarthritis pain. This engineered antibody uniquely targets sensory growth element , blocking its function and thereby diminishing inflammation within affected areas . The experimental data surrounding 880266-57-9 highlights its capacity to deliver significant suffering relief while possibly avoiding the requirement for traditional analgesics. Further investigation are actively underway to completely evaluate its lasting safety and performance.
Comprehending Tanezumab's Part in Pain Alleviation: An Immune Protein View
Tanezumab, a novel treatment approach, offers a distinct pathway in long-term pain management. As a humanized antibody, it specifically targets and inhibits nerve growth factor (NGF), a critical molecule participating in nerve ache signaling. Unlike traditional narcotic medications, tanezumab’s protein mechanism allows for a focused precise action, arguably lessening the risk of some frequent side consequences connected with generalized pain relief. However, its protein nature necessitates a careful evaluation of anticipated body's responses and extended consequences when employed within a complete pain treatment program.
Tanezumab Compound (880266-57-9): Purity , Grade & Uses
The Tanezumab Solution with the identifier 880266-57-9 is a critical component in various scientific applications, particularly concerning chronic inflammation treatment development. Achieving a high standard of consistency is paramount; therefore, rigorous testing protocols are employed to guarantee its fitness for specific use. Our manufacturing process focuses on ensuring purity , employing sophisticated purification techniques to remove impurities . Typical specifications include a >95% purity assessment as determined by Chromatography and comprehensive examination for biochemical integrity. The main applications revolve around its role as a scientific resource for investigating processes of arthritis progression and next-generation therapeutic interventions . Biomedical Investigations Therapeutic DevelopmentMechanism Studies
A Science Regarding Tanezumab:
Tanezumab, identified by the molecular identifier 880266-57-9, represents a innovative biological immunoglobulin targeting pain-sensing factor substance receptor (NGF). Its mode of effect revolves about specifically connecting to NGF, thereby reducing its activity and following signal pathway. Investigators have demonstrated that this molecular agent provides opportunity for alleviating persistent suffering, particularly in diseases like arthritic conditions and peripheral back ache. Additional research are ongoing to completely define its impact and well-being characteristics.
Recent Developments in This Investigation: Focusing on the Its Substance
Current analyses surrounding tanezumab, a novel therapeutic agent, are increasingly focused on defining the role of the specific reagent, 880266-57-9. The identification and detailed investigation of such chemical entity seems necessary for optimizing the drug's performance and reducing potential negative effects. Early results reveal that 880266-57-9 plays a significant part in tanezumab’s mechanism of action. Additional exploration are needed to fully elucidate the reagent’s influence.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS click here number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}